Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta Drugs's revenue for the
three
months ended in Mar. 2026 was ₹940 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,812 Mil.
Beta Drugs's Revenue per Share for the
three
months ended in Mar. 2026 was ₹92.73.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹178.80.
Warning Sign:
Beta Drugs Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Beta Drugs was 5.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 19.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 26.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 30.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Beta Drugs's highest 3-Year average Revenue per Share Growth Rate was 477.60% per year. The lowest was 19.00% per year. And the median was 35.70% per year.
Beta Drugs (NSE:BETA) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Beta Drugs Revenue Related Terms
Beta Drugs Revenue Historical Data
* Premium members only.
The historical data trend for Beta Drugs's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Revenue distribution charts can be found below:
* The bar in red indicates where Beta Drugs's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,812 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a Revenue of ₹1,812 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Beta Drugs and its competitors.
Is Beta Drugs' Revenue too high?
Beta Drugs' current Revenue is ₹1,812 Mil. Overall, Beta Drugs has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Revenue compare to ZTS?
Beta Drugs' Revenue of ₹1,812 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Beta Drugs and its competitors. Beta Drugs's current Revenue is ₹1,812 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,993.18, compared to a current price of ₹2,233.20 — trading 12% above its estimated fair value. The current Revenue is ₹1,812 Mil. Beta Drugs' overall GF Score™ is 94/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Revenue is ₹1,812 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,233.20 is trading 12% above its estimated GF Value™ of ₹1,993.18.
GuruFocus considers Beta Drugs to be Fairly Valued.
Key valuation signals for NSE:BETA:
Revenue: ₹1,812 Mil
GF Value™: ₹1,993.18 vs. price of ₹2,233.20 (12% above fair value)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
94GF Score
Get the complete analysis for NSE:BETA
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
